<- Go Home

CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.

Market Cap

$3.7B

Volume

1.9M

Cash and Equivalents

$206.5M

EBITDA

-$101.0M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

-$49.7M

Profit Margin

-160.03%

52 Week High

$32.50

52 Week Low

$7.26

Dividend

N/A

Price / Book Value

12.65

Price / Earnings

-32.74

Price / Tangible Book Value

12.65

Enterprise Value

$3.4B

Enterprise Value / EBITDA

-34.17

Operating Income

-$101.7M

Return on Equity

-64.17%

Return on Assets

-22.05

Cash and Short Term Investments

$394.3M

Debt

$114.5M

Equity

$292.3M

Revenue

$31.1M

Unlevered FCF

-$43.0M

Sector

Pharmaceuticals

Category

N/A

Company Stock Pitches